Cholestenone 5 alpha-Reductase
"Cholestenone 5 alpha-Reductase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An oxidoreductase that catalyzes the conversion of 3-oxo-delta4 steroids into their corresponding 5alpha form. It plays an important role in the conversion of TESTOSTERONE into DIHYDROTESTOSTERONE and PROGESTERONE into DIHYDROPROGESTERONE.
| Descriptor ID |
D042944
|
| MeSH Number(s) |
D08.811.682.660.200
|
| Concept/Terms |
Cholestenone 5 alpha-Reductase- Cholestenone 5 alpha-Reductase
- 5 alpha-Reductase, Cholestenone
- Cholestenone 5 alpha Reductase
- alpha-Reductase, Cholestenone 5
- 4-Ene Steroid 5 alpha-Reductase
- 4 Ene Steroid 5 alpha Reductase
- 5 alpha-Reductase
- 5 alpha Reductase
|
Below are MeSH descriptors whose meaning is more general than "Cholestenone 5 alpha-Reductase".
Below are MeSH descriptors whose meaning is more specific than "Cholestenone 5 alpha-Reductase".
This graph shows the total number of publications written about "Cholestenone 5 alpha-Reductase" by people in this website by year, and whether "Cholestenone 5 alpha-Reductase" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Cholestenone 5 alpha-Reductase" by people in Profiles.
-
5a-reductase type 3 enzyme in benign and malignant prostate. Prostate. 2014 Feb; 74(3):235-49.
-
Androgen regulation of 5a-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One. 2011; 6(12):e28840.
-
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res. 2011 Sep 15; 17(18):5844-9.
-
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105.
-
Benign prostatic hyperplasia. Part 2--management. BMJ. 2008 Jan 26; 336(7637):206-10.
-
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Jul 04; 99(13):1025-35.
-
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004 May; 89(5):2179-84.
-
The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions. Urol Clin North Am. 2004 May; 31(2):213-8.
-
Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 2004 Apr; 25(2):203-22.